Insights into the Urology/Oncology Perspective
This program is designed to enlighten the Prostate cancer care team about the importance of PSMA Imaging and its impact on patient management and care. This multidisciplinary panel discussion provides clinical perspectives on the utility and the implications of using PSMA PET/CT as a theranostic approach and identifies best practices through the shared clinical experiences of Urologists and Medical Oncologists.
This program is designed with the following educational objectives:
Reader Training is an educational resource from Telix Pharmaceuticals, makers of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide Injection), designed to improve PSMA-11 PET/CT reader skills and increase confidence in identifying pathology while following guidelines to optimize PET/CT reading. Learning modules will include, learning objectives, case study reviews and teaching points presented with video, slides, supporting resources and clinical articles.
History: Patient is a 72-year-old male with history of prostate carcinoma, diagnosed in 2020. Gleason 4+3 =7. Status post radiation therapy, ADT and Lu-PSMA therapy. Presents now with rising PSA values, most recently at 5.6 ng/dl.
The content in this section links to a third-party website. Therefore, to view this educational resource, you will be be leaving TelixU and redirected to another website
Disclaimer: Telix is proud to sponsor this educational series with Urology Times®, however, Telix did not participate in the creation of this educational content and is not responsible for any content on or the privacy practices of third-party sites.
Key opinion leaders discuss the latest PSMA-PET imaging updates for prostate cancer and consider how real-world practice has evolved.